Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

doi:10.3748/wjg.v28.i17.1768

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4761)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

292

WORD

119

HTML

2771

Figures (1-4)

326

Sum=3508

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

209

Download

269

Sum=478

Publishing Process of This Article

Item

Count

Browse

315

Download

460

Sum=775

May 7, 2022 (publication date) through Aug 30, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. May 7, 2022; 28(17): 1768-1780
Published online May 7, 2022. doi: 10.3748/wjg.v28.i17.1768

Full Size Figure Download Figure

Figure 1 ⁶⁸Ga DOTATATE positron emission tomography/computed tomography transaxial fusion and whole body projection positron emission tomography. A: A normal patient; B: A different patient with well-differentiated pancreatic neuroendocrine tumor with nodal, bone, and liver metastases. Small liver metastases can be seen SUVmax = 10.4 (arrow).

Citation: Grey N, Silosky M, Lieu CH, Chin BB. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World J Gastroenterol 2022; 28(17): 1768-1780
URL: https://www.wjgnet.com/1007-9327/full/v28/i17/1768.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i17.1768